Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q4 2020 · 10-K
Revenue$789.81M$789.81Mderived+26.5% vs Q4 2019 Net Income$839.20M$839.20M+51.6% vs Q4 2019 EPS Diluted$27.81$27.81+51.9% vs Q4 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
+39.3%
Operating Incomederived$185,611,000+213.5% Operating Cash Flowderived$294,378,000+84.2% Free Cash Flowderived$245,499,000+77.6% Margins · derivedGross margin58.3%+5.3 pt vs Q4 2019
Operating margin23.5%+14.0 pt vs Q4 2019
Net margin106.3%+17.6 pt vs Q4 2019
ended Dec 31, 2020 · filed Feb 16, 2021 · 47 d after period end